ENG/中
老虎证券
行情
交易
收费
下载
优惠与活动
帮助
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
股权激励
关于
登录
立即注册
Toggle
港股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
药明合联
56.150
+5.350
10.53%
手动刷新
成交量：
1,070.67万
成交额：
5.92亿
市值：
706.37亿
市盈率：
67.65
高：
56.950
开：
52.600
低：
52.600
收：
50.800
52周最高：
85.500
52周最低：
24.700
股本：
12.58亿
香港流通股本：
12.58亿
量比：
2.45
换手率：
0.85%
股息：
- -
股息率：
- -
每股收益(LYR):
0.830
净资产收益率：
17.05%
总资产收益率：
8.60%
市净率：
5.80
市盈率(LYR):
67.65
市销率:
10.46
数据加载中...
总览
公司
新闻资讯
公告
从“赋能者”到“定义者”，CRDMO行业龙头药明合联(02268)的持续进化与价值跃迁
智通财经
·
昨天
《大行》大摩予药明合联(02268.HK)评级“增持” 目标价86元
阿斯达克财经
·
昨天
触底反弹！华宝基金港股通创新药ETF、港股通医疗ETF携手冲高3%！业绩超预期，药明合联、药明康德强势领涨
新浪基金
·
昨天
《大行》瑞银下调药明合联(02268.HK)目标价至90.4元 产能扩张进度良好
阿斯达克财经
·
昨天
港股异动 | 创新药概念股走高，药明合联涨超8%
老虎资讯综合
·
昨天
异动解读 | 业绩超预期！药明合联盘中大涨5.22%
异动解读
·
昨天
【券商聚焦】中信证券：GDF-15阻断剂有望在未来获批治疗肿瘤恶病质
金吾财讯
·
昨天
药明合联2025年业绩表现卓越，巩固其在生物偶联药物CRDMO领域的全球领导地位
美股速递
·
03/23
药明合联(02268)2025年业绩高增延续，“全球扩张+技术赋能”牢筑行业龙头地位
智通财经
·
03/23
药明合联(02268)2025年收益净利双增长 公司拥有人应占经调整纯利约15.59亿元 同比增长69.9%
智通财经网
·
03/23
【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理
金吾财讯
·
03/23
港股异动 | 东曜药业-B(01875)再涨超11% 年内股价已翻倍 药明合联收购要约正式生效
智通财经
·
03/20
【券商聚焦】中国银河：“十五五”首次将生物医药列为国家新兴支柱产业，持续发力研发创新
金吾财讯
·
03/20
港股异动 | 东曜药业-B(01875)涨超9% 药明合联已取得公司60%股权有效接纳 收购要约正式生效
智通财经
·
03/19
港股异动 | 东曜药业-B(01875)午后涨超5% 药明合联收购条件到期未达成 要约期已延长
智通财经
·
03/17
港股生物医药概念股走高，药明合联涨近7%，荣昌生物涨超5%
老虎资讯综合
·
03/17
药明合联（02268）收购东曜药业（01875）首轮接纳达46.54%，要约延至3月27日
公告速递
·
03/13
药明合联(02268)出现大手买入9.1万股，成交价$55.5，涉资505.05万
阿斯达克财经
·
03/12
【券商聚焦】中泰国际：中央政府首次将生物医药列入新兴支柱产业 预计今后将大力支持生物医药行业发展
金吾财讯
·
03/12
每日卖空追踪 | 药明合联 03月10日卖空量成交41万股，卖空比例为12.31%
市场透视
·
03/10
更多
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02268/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02268","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02268\",,,,,undefined,":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":56.15,"timestamp":1774339700003,"preClose":50.8,"halted":0,"volume":10706701,"delay":0,"changeRate":0.1053149606299213,"floatShares":1258000000,"shares":1258000000,"eps":0.829999,"marketStatus":"未开盘","change":5.35,"latestTime":"03-24 16:08:20","open":52.6,"high":56.95,"low":52.6,"amount":591964253,"amplitude":0.08563,"askPrice":56.15,"askSize":31000,"bidPrice":56.1,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":1.118336,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774402200000},"marketStatusCode":0,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":50.8,"openAndCloseTimeList":[[1774315800000,1774324800000],[1774328400000,1774339200000]],"volumeRatio":2.4506331379903905,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02268\",,,,,undefined,":{"symbol":"02268","floatShares":1258000000,"roa":"8.60%","roe":"17.05%","lyrEps":0.829999,"volumeRatio":2.4506331379903905,"shares":1258000000,"dividePrice":0,"high":56.95,"amplitude":0.08563,"preClose":50.8,"low":52.6,"week52Low":24.7,"pbRate":"5.80","psRate":"10.46","week52High":85.5,"institutionHeld":0,"latestPrice":56.15,"committee":-0.823529,"eps":0.829999,"divideRate":0,"volume":10706701,"delay":0,"ttmEps":1.118336,"open":52.6,"prevYearClose":60.75,"prevWeekClose":52.95,"prevMonthClose":63.15,"prevQuarterClose":60.75,"fiveDayClose":55.8,"twentyDayClose":64.55,"sixtyDayClose":67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02268\",params:#limit:5,,,undefined,":[{"date":"2026-04-29","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1777426200000,"name":null,"time":"","dateTimestamp":1777392000000,"actualEps":null},{"date":"2026-03-23","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774229400000,"name":null,"time":"","dateTimestamp":1774195200000,"actualEps":null},{"date":"2025-08-18","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-03-24","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-20","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724117400000,"name":null,"time":"","dateTimestamp":1724083200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02268\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02268\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3,"buy":0.7,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7,"analysts":20,"updateTime":1770393600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02268\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02268","date":"2026-03-23","current":50.208524,"percent":0.135182,"low":30.568632,"twenty":45.034402,"median":58.324859,"eighty":71.812082,"high":153.052589,"avg":63.9688,"sd":26.173434,"marketCap":63906029414},"quantilePoints":[{"date":"2023-11-17","current":130.035431,"twenty":0.435785,"median":0.444801,"eighty":2.787891,"marketCap":32996488000},{"date":"2023-11-24","current":133.579843,"twenty":0.435785,"median":0.444801,"eighty":2.810425,"marketCap":34174934000},{"date":"2023-12-01","current":147.707211,"twenty":0.435785,"median":0.444801,"eighty":2.852893,"marketCap":37945961200},{"date":"2023-12-08","current":132.646927,"twenty":0.435785,"median":0.444801,"eighty":2.935117,"marketCap":33939244800},{"date":"2023-12-15","current":138.75437,"twenty":0.435785,"median":0.444801,"eighty":3.039251,"marketCap":35706913800},{"date":"2023-12-22","current":153.052589,"twenty":0.435785,"median":0.444801,"eighty":3.172504,"marketCap":39360096400},{"date":"2023-12-29","current":145.85951,"twenty":0.435785,"median":0.444801,"eighty":3.326638,"marketCap":37710272000},{"date":"2024-01-05","current":142.305018,"twenty":0.435785,"median":0.444801,"eighty":3.599996,"marketCap":36531826000},{"date":"2024-01-12","current":138.558869,"twenty":0.435785,"median":0.444801,"eighty":3.622774,"marketCap":35589069200},{"date":"2024-01-19","current":141.046625,"twenty":0.435785,"median":0.444801,"eighty":3.635946,"marketCap":36178292200},{"date":"2024-01-26","current":116.23004,"twenty":0.435785,"median":0.444801,"eighty":3.642902,"marketCap":29696839200},{"date":"2024-02-02","current":82.111439,"twenty":0.435785,"median":0.444801,"eighty":3.654128,"marketCap":20952769880},{"date":"2024-02-09","current":67.278987,"twenty":0.435825,"median":0.445043,"eighty":3.68657,"marketCap":17252449440},{"date":"2024-02-16","current":66.713097,"twenty":0.435798,"median":0.44487,"eighty":3.704054,"marketCap":17111035920},{"date":"2024-02-23","current":82.124312,"twenty":0.435798,"median":0.44487,"eighty":3.728385,"marketCap":20952769880},{"date":"2024-03-01","current":86.135235,"twenty":0.435812,"median":0.444939,"eighty":3.767614,"marketCap":21989802360},{"date":"2024-03-08","current":96.662972,"twenty":0.435812,"median":0.444939,"eighty":3.804363,"marketCap":24688443700},{"date":"2024-03-15","current":72.134287,"twenty":0.435812,"median":0.444939,"eighty":3.87411,"marketCap":18407326520},{"date":"2024-03-22","current":82.739174,"twenty":0.435812,"median":0.444939,"eighty":3.907844,"marketCap":21094183400},{"date":"2024-03-28","current":70.236298,"twenty":0.435812,"median":0.444939,"eighty":3.924107,"marketCap":21565561800},{"date":"2024-04-05","current":69.514463,"twenty":0.435772,"median":0.444721,"eighty":3.932321,"marketCap":21329872600},{"date":"2024-04-12","current":72.929575,"twenty":0.435785,"median":0.444801,"eighty":3.970214,"marketCap":22390474000},{"date":"2024-04-19","current":66.691535,"twenty":0.435785,"median":0.444801,"eighty":4.01279,"marketCap":20457822560},{"date":"2024-04-26","current":78.851628,"twenty":0.435812,"median":0.444939,"eighty":62.837086,"marketCap":24158143000},{"date":"2024-05-03","current":79.483533,"twenty":0.435812,"median":0.444939,"eighty":66.70016,"marketCap":24334909900},{"date":"2024-05-10","current":73.189732,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":22461180760},{"date":"2024-05-17","current":65.221538,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":19986444160},{"date":"2024-05-24","current":58.278715,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":17818103520},{"date":"2024-05-31","current":59.948577,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":18347300940},{"date":"2024-06-07","current":58.299117,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":17820354960},{"date":"2024-06-14","current":64.156468,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":19592809620},{"date":"2024-06-21","current":70.500097,"twenty":0.435812,"median":0.444939,"eighty":69.593748,"marketCap":21485024730},{"date":"2024-06-28","current":68.013259,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":20718557850},{"date":"2024-07-05","current":61.893714,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":18850294830},{"date":"2024-07-12","current":63.530585,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":19377240810},{"date":"2024-07-19","current":56.933019,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":17365265250},{"date":"2024-07-26","current":56.800526,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":17389217340},{"date":"2024-08-02","current":69.358964,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":21221551740},{"date":"2024-08-09","current":72.710245,"twenty":0.435812,"median":0.444939,"eighty":70.597189,"marketCap":22395204150},{"date":"2024-08-16","current":74.003491,"twenty":0.435812,"median":0.444939,"eighty":70.930659,"marketCap":22802389680},{"date":"2024-08-23","current":35.050376,"twenty":0.435812,"median":0.44524,"eighty":71.736965,"marketCap":22742129354},{"date":"2024-08-30","current":36.779427,"twenty":0.435812,"median":0.445278,"eighty":71.736965,"marketCap":24024219892},{"date":"2024-09-06","current":36.193339,"twenty":0.435812,"median":0.445278,"eighty":71.736965,"marketCap":23652773101},{"date":"2024-09-13","current":36.950123,"twenty":0.435812,"median":0.445611,"eighty":71.736965,"marketCap":24084130665},{"date":"2024-09-20","current":36.912594,"twenty":0.435798,"median":0.445732,"eighty":71.812082,"marketCap":24203952211},{"date":"2024-09-27","current":41.596291,"twenty":0.435798,"median":0.446064,"eighty":71.812082,"marketCap":27439133942},{"date":"2024-10-04","current":49.267448,"twenty":0.435798,"median":0.446181,"eighty":71.812082,"marketCap":32351817312},{"date":"2024-10-10","current":43.61955,"twenty":0.435812,"median":0.446472,"eighty":71.736965,"marketCap":28457617080},{"date":"2024-10-18","current":43.201999,"twenty":0.435798,"median":0.446694,"eighty":71.812082,"marketCap":28038241670},{"date":"2024-10-25","current":43.020102,"twenty":0.435798,"median":0.446852,"eighty":71.812082,"marketCap":27918420124},{"date":"2024-11-01","current":41.699543,"twenty":0.435798,"median":0.446999,"eighty":71.812082,"marketCap":27079669305},{"date":"2024-11-08","current":47.130705,"twenty":0.435852,"median":0.447279,"eighty":71.812082,"marketCap":30374761809},{"date":"2024-11-15","current":46.740281,"twenty":0.435852,"median":0.44753,"eighty":71.812082,"marketCap":29895475627},{"date":"2024-11-22","current":46.01742,"twenty":0.435852,"median":0.447785,"eighty":71.812082,"marketCap":29416189444},{"date":"2024-11-29","current":51.670123,"twenty":0.435852,"median":0.448371,"eighty":71.812082,"marketCap":33010835812},{"date":"2024-12-06","current":54.048034,"twenty":0.435852,"median":0.449445,"eighty":71.812082,"marketCap":34448694360},{"date":"2024-12-13","current":58.707371,"twenty":0.435852,"median":0.45138,"eighty":71.812082,"marketCap":37384322227},{"date":"2024-12-20","current":60.54506,"twenty":0.435852,"median":35.016583,"eighty":71.812082,"marketCap":38342894592},{"date":"2024-12-27","current":58.22519,"twenty":0.435852,"median":35.863906,"eighty":71.812082,"marketCap":36845125272},{"date":"2025-01-03","current":57.033249,"twenty":0.435852,"median":36.241161,"eighty":71.812082,"marketCap":36126195998},{"date":"2025-01-10","current":62.66188,"twenty":0.435852,"median":36.730689,"eighty":71.812082,"marketCap":39541110048},{"date":"2025-01-17","current":54.642634,"twenty":0.436361,"median":37.212991,"eighty":71.812082,"marketCap":34508605132},{"date":"2025-01-24","current":54.868028,"twenty":0.436606,"median":39.470644,"eighty":71.812082,"marketCap":34868069769},{"date":"2025-01-28","current":52.331181,"twenty":0.436643,"median":41.238065,"eighty":71.736965,"marketCap":33430211222},{"date":"2025-02-07","current":57.910706,"twenty":0.437089,"median":42.380717,"eighty":71.8872,"marketCap":36785214499},{"date":"2025-02-14","current":56.82028,"twenty":0.437089,"median":43.020102,"eighty":71.8872,"marketCap":36006374452},{"date":"2025-02-21","current":70.802488,"twenty":0.437089,"median":44.139364,"eighty":71.8872,"marketCap":45112811918},{"date":"2025-02-28","current":60.65941,"twenty":0.437089,"median":45.078416,"eighty":71.8872,"marketCap":38522626910},{"date":"2025-03-07","current":67.088057,"twenty":0.437583,"median":46.607669,"eighty":71.962317,"marketCap":42776291779},{"date":"2025-03-14","current":72.98104,"twenty":0.438098,"median":47.703312,"eighty":71.990989,"marketCap":46550670465},{"date":"2025-03-21","current":80.244903,"twenty":0.438098,"median":49.592986,"eighty":72.978175,"marketCap":51163799971},{"date":"2025-03-28","current":47.906694,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":54840613248},{"date":"2025-04-03","current":43.121995,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":49380552191},{"date":"2025-04-11","current":35.581021,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":40380451549},{"date":"2025-04-17","current":33.597127,"twenty":0.4381,"median":49.700845,"eighty":72.980467,"marketCap":38220427395},{"date":"2025-04-25","current":39.226609,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":44663120338},{"date":"2025-05-02","current":40.829264,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":46586700218},{"date":"2025-05-09","current":38.818219,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":44603008467},{"date":"2025-05-16","current":39.608151,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":45882474676},{"date":"2025-05-23","current":38.196121,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":44379117053},{"date":"2025-05-30","current":41.172242,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":48047309655},{"date":"2025-06-06","current":42.866418,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":50152010328},{"date":"2025-06-13","current":46.041552,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":53888090995},{"date":"2025-06-20","current":41.240748,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":48174509918},{"date":"2025-06-27","current":40.971553,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":47994081042},{"date":"2025-07-04","current":46.000985,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":53888090995},{"date":"2025-07-11","current":47.288014,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":55339986740},{"date":"2025-07-18","current":50.925924,"twenty":0.438098,"median":50.569275,"eighty":72.98104,"marketCap":59550637905},{"date":"2025-07-25","current":57.660678,"twenty":0.438098,"median":51.683826,"eighty":72.98104,"marketCap":67671179437},{"date":"2025-08-01","current":57.245588,"twenty":0.438098,"median":52.545804,"eighty":72.98104,"marketCap":66768897045},{"date":"2025-08-08","current":57.73965,"twenty":0.43811,"median":53.257543,"eighty":72.98104,"marketCap":67513611340},{"date":"2025-08-15","current":64.222783,"twenty":31.309336,"median":54.856958,"eighty":72.98104,"marketCap":74981664691},{"date":"2025-08-22","current":48.130228,"twenty":34.419063,"median":54.952855,"eighty":72.98104,"marketCap":69501077151},{"date":"2025-08-29","current":46.988345,"twenty":35.581021,"median":54.952855,"eighty":72.98104,"marketCap":68176099944},{"date":"2025-09-05","current":54.370406,"twenty":36.186031,"median":55.113399,"eighty":72.98104,"marketCap":78808670381},{"date":"2025-09-12","current":57.034752,"twenty":36.596757,"median":55.50873,"eighty":72.98104,"marketCap":82819396110},{"date":"2025-09-19","current":59.571504,"twenty":36.911418,"median":56.000464,"eighty":72.98104,"marketCap":86441593568},{"date":"2025-09-26","current":63.204858,"twenty":37.279949,"median":56.495601,"eighty":72.98104,"marketCap":91475834102},{"date":"2025-10-03","current":72.025865,"twenty":37.670679,"median":56.699916,"eighty":72.980467,"marketCap":104491187679},{"date":"2025-10-10","current":60.90024,"twenty":38.189538,"median":56.97042,"eighty":72.98104,"marketCap":88221995708},{"date":"2025-10-17","current":57.936353,"twenty":38.732076,"median":57.121577,"eighty":72.98104,"marketCap":83863080123},{"date":"2025-10-24","current":59.821834,"twenty":39.226609,"median":57.526112,"eighty":72.98104,"marketCap":86623810506},{"date":"2025-10-31","current":63.630196,"twenty":39.774995,"median":57.92353,"eighty":72.98104,"marketCap":92275860553},{"date":"2025-11-07","current":58.827143,"twenty":40.354886,"median":58.251953,"eighty":72.98104,"marketCap":85257233036},{"date":"2025-11-14","current":59.953959,"twenty":41.172242,"median":58.455089,"eighty":72.98104,"marketCap":87136525462},{"date":"2025-11-21","current":57.356344,"twenty":41.596291,"median":58.554061,"eighty":72.98104,"marketCap":83322340564},{"date":"2025-11-28","current":56.291024,"twenty":42.018405,"median":58.564991,"eighty":72.98104,"marketCap":82071768197},{"date":"2025-12-05","current":57.95451,"twenty":42.42494,"median":58.564991,"eighty":72.98104,"marketCap":84642388897},{"date":"2025-12-12","current":56.819112,"twenty":42.866418,"median":58.860686,"eighty":72.98104,"marketCap":83137635317},{"date":"2025-12-19","current":59.902097,"twenty":43.024716,"median":58.930609,"eighty":72.98104,"marketCap":87855221510},{"date":"2025-12-24","current":53.787136,"twenty":43.211711,"median":58.930609,"eighty":72.98104,"marketCap":79132453088},{"date":"2026-01-02","current":52.131715,"twenty":43.875774,"median":58.940897,"eighty":73.022778,"marketCap":76998826280},{"date":"2026-01-09","current":60.097118,"twenty":44.079539,"median":58.920321,"eighty":72.979321,"marketCap":88984788643},{"date":"2026-01-16","current":59.868148,"twenty":44.329264,"median":59.011667,"eighty":72.978748,"marketCap":88933823858},{"date":"2026-01-23","current":58.064858,"twenty":44.542103,"median":59.011667,"eighty":72.978748,"marketCap":86172293688},{"date":"2026-01-30","current":52.991062,"twenty":44.673253,"median":58.945496,"eighty":72.939295,"marketCap":79001941874},{"date":"2026-02-06","current":53.067413,"twenty":44.72485,"median":58.907275,"eighty":72.769063,"marketCap":79316440050},{"date":"2026-02-13","current":54.647287,"twenty":44.764796,"median":58.707371,"eighty":72.713983,"marketCap":82146923636},{"date":"2026-02-20","current":54.893728,"twenty":44.79956,"median":58.576126,"eighty":72.595053,"marketCap":82398522177},{"date":"2026-02-27","current":52.350133,"twenty":44.938454,"median":58.531174,"eighty":72.112603,"marketCap":79442239320},{"date":"2026-03-06","current":49.767005,"twenty":45.116803,"median":58.469542,"eighty":72.01889,"marketCap":74913465582},{"date":"2026-03-13","current":45.00506,"twenty":45.116803,"median":58.377121,"eighty":71.985255,"marketCap":68057405340},{"date":"2026-03-20","current":44.215816,"twenty":45.114658,"median":58.350601,"eighty":71.8872,"marketCap":66610713729},{"date":"2026-03-23","current":42.342276,"twenty":45.034402,"median":58.324859,"eighty":71.812082,"marketCap":63906029414}],"updateTime":1774388919532},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02268\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621550170","title":"从“赋能者”到“定义者”，CRDMO行业龙头药明合联(02268)的持续进化与价值跃迁","url":"https://stock-news.laohu8.com/highlight/detail?id=2621550170","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621550170?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 14:27","pubTimestamp":1774333622,"startTime":"0","endTime":"0","summary":"一份亮眼的年度答卷，将全球生物偶联药CRDMO龙头药明合联推至聚光灯下。近日，药明合联与Earendil Labs达成潜在交易总额高达8.85亿美元的WuXiTecan-2技术授权合作。Part 2 项目漏斗的质量革命：从“赢得分子”到“锁定未来”财报显示，药明合联累计服务超1000个发现阶段项目，252个进入iCMC开发阶段，2025年有69个项目成功转化。根据财报显示，药明合联海外收入占比已达85%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","02268","SG9999014674.SGD","LU2488822045.USD"],"gpt_icon":0},{"id":"2621119032","title":"《大行》大摩予药明合联(02268.HK)评级“增持” 目标价86元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621119032","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621119032?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 10:55","pubTimestamp":1774320900,"startTime":"0","endTime":"0","summary":"大摩发表研究报告指，药明合联(02268.HK) 去年收入达59.44亿元人民币(下同)，按年升46.7%，毛利达21.39亿元，按年升72.5%，经调整净利润达15.59亿元，按年升69.9%，均略高于早前公布的盈喜预测。该行提及，药明合联重申2025至2030年收入年均复合增长率指引为30%至35%，高于弗若斯特沙利文对行业预测的25.6%水平。该行予其目标价86港元，评级“增持”。(ca/j)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-23 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231107083824175_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231107083824175_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511767/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511767/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"2621314220","title":"触底反弹！华宝基金港股通创新药ETF、港股通医疗ETF携手冲高3%！业绩超预期，药明合联、药明康德强势领涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2621314220","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621314220?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 10:05","pubTimestamp":1774317900,"startTime":"0","endTime":"0","summary":"3月24日，港股全线反弹，医药板块高弹领涨，创新药产业链急速修复，100%创新药研发标的——港股通创新药ETF、高CXO含量的港股通医疗ETF华宝双双高开，盘中一度涨超3%。昨日两只ETF均创下历史收盘新低。 个股方面，创新药龙头回暖，港股通创新药ETF权重股康方生物、信达生物、石药集团集体涨超2%。港股通医疗ETF华宝持仓药明系CXO龙头绩后大涨，药明合联涨超8%，药明康德涨超7%。 消息面，昨日晚间，药明系上市公司披露2025年业绩。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-24/doc-inhrzysz3556834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0320764599.SGD","LU1046422090.SGD","LU2495084118.USD","LU0456842615.SGD","LU2242644610.SGD","BK1583","02268","LU1997244956.HKD","BK0216","LU2488822045.USD","LU2328871848.SGD","LU1979443071.USD","LU0708995583.HKD","LU1997245177.USD","BK1141","LU1934453819.USD","SG9999014674.SGD","LU0052750758.USD","LU1808992512.USD","LU1969619763.USD","603259","02359","BK1576","520880","LU1997245094.SGD","LU2045819591.USD","LU2125910500.SGD"],"gpt_icon":0},{"id":"2621034874","title":"《大行》瑞银下调药明合联(02268.HK)目标价至90.4元 产能扩张进度良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2621034874","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621034874?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 09:59","pubTimestamp":1774317540,"startTime":"0","endTime":"0","summary":"瑞银发表研究报告指，药明合联去年下半年业绩符合其初步数据，收入按年升35.9%至32.4亿元人民币(下同)，股东应占纯利7.35亿元，按年升26.4%。2025全年收入及经调整纯利分别按年升46.7%及69.9%。另外，公司的新加坡厂房将于2026年上半年投产，目前已收到10个后期临床制程方案请求，并已与海外客户签订多个项目。该行微调药明合联盈利预测，轻微上调2026及2027年开支预测，目标价由95.7港元下调至90.4港元，认为估值吸引，维持“买入”评级。沽空资料截至 2026-03-23 16:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231117104105862_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231117104105862_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511729/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511729/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"1143024702","title":"港股异动 | 创新药概念股走高，药明合联涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143024702","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143024702?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 09:42","pubTimestamp":1774316564,"startTime":"0","endTime":"0","summary":"3月24日，港股创新药概念股集体走高，$药明合联(02268)$涨超8%，$药明康德(02359)$涨超6%，$康诺亚-B(02162)$涨超4%，$药明生物(02269)$涨超3%，$石药集团(01093)$涨近3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014674.SGD","BK1141","BK1574","02268","BK4585","LU2488822045.USD","BK1161","BK4588"],"gpt_icon":0},{"id":"1158899695","title":"异动解读 | 业绩超预期！药明合联盘中大涨5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158899695","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158899695?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 09:33","pubTimestamp":1774315994,"startTime":"0","endTime":"0","summary":"药明合联(02268.HK)今日盘中大涨5.22%，表现显著强于大市。消息面上，公司于前一交易日盘后公布了2025年度业绩报告。数据显示，公司全年收益达59.44亿元人民币，按年大幅增长46.7%；录得纯利14.8亿元人民币，同比增长38.4%。这份远超市场预期的亮眼成绩单，是推动股价今日走强的主要动力。强劲的业绩增长反映了公司主营业务良好的发展态势与盈利能力，增强了投资者对其未来发展的信心，从而吸引了资金的积极买入。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02268"],"gpt_icon":0},{"id":"2621052036","title":"【券商聚焦】中信证券：GDF-15阻断剂有望在未来获批治疗肿瘤恶病质","url":"https://stock-news.laohu8.com/highlight/detail?id=2621052036","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621052036?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 09:01","pubTimestamp":1774314061,"startTime":"0","endTime":"0","summary":"目前GDF-15阻断剂行业处于临床开发阶段，尚无任何药物获批，多数临床管线处于早期阶段，进度最快的为辉瑞公司和CatalYm公司。鉴于Ponsegromab在II期临床试验中的优异结果以及Ponsegromab的II/III期临床试验设计，该机构认为其有望获批治疗肿瘤恶病质，成为GDF-15阻断剂上市后第一个适应症。后续如果Ponsegromab成功上市以及Visugromab读出积极数据，将催化GDF-15阻断剂市场快速增长。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977070","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","LU2328871848.SGD","IE00BPRC5H50.USD","BK1585","BK1141","03933","01530","BK1147","SG9999014674.SGD","LU0417516902.SGD","LU1580142542.USD","LU1997245094.SGD","02367","BK0012","LU2289578879.USD","BK1207","LU1781817850.SGD","LU0405327494.USD","BK1593","LU1303224171.USD","06821","01789","BK1515","02228","06030","HK0000165453.HKD","06160","BK1564","02268","BK1574","LU0348735423.USD","01099","LU0348825331.USD","LU1794554557.SGD","IE00B543WZ88.USD","LU1064131003.USD","BK0276","LU1328615791.USD","09926","09688","600030","LU0640798160.USD","BK1191","LU0348783233.USD","LU1255011170.USD","LU0405327148.USD","02196","LU1655091616.SGD","BK1161","LU0307460666.USD"],"gpt_icon":0},{"id":"1139697902","title":"药明合联2025年业绩表现卓越，巩固其在生物偶联药物CRDMO领域的全球领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1139697902","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139697902?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 21:17","pubTimestamp":1774271838,"startTime":"0","endTime":"0","summary":"药明合联在2025年取得了卓越的业绩表现，进一步巩固了其在生物偶联药物合同研究、开发与生产（CRDMO）领域的全球领导地位。公司展现出强劲的增长势头和业务韧性，持续获得全球合作伙伴的广泛认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1141","02268","SG9999014674.SGD"],"gpt_icon":0},{"id":"2621520705","title":"药明合联(02268)2025年业绩高增延续，“全球扩张+技术赋能”牢筑行业龙头地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2621520705","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621520705?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 20:26","pubTimestamp":1774268789,"startTime":"0","endTime":"0","summary":"财务与业务数据亮眼，彰显龙头“确定性”药明合联2025年的财务表现，诠释了其在高速成长赛道中的龙头溢价。在自身有机增长动能充沛之际，药明合联把握战略契机，于2026年初启动对东曜药业的控股收购，这并非简单的规模叠加，而是在“有机扩展+战略并购”双轮驱动下，进一步深化全球领导地位的战略棋局。收购预计在2026年3月底完成，随后进入全面整合阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"药明合联(02268)2025年业绩高增延续，“全球扩张+技术赋能”牢筑行业龙头地位","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","SG9999014674.SGD","02268","LU2488822045.USD"],"gpt_icon":1},{"id":"2621703218","title":"药明合联(02268)2025年收益净利双增长 公司拥有人应占经调整纯利约15.59亿元 同比增长69.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703218","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703218?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 20:15","pubTimestamp":1774268148,"startTime":"0","endTime":"0","summary":"药明合联(02268)公布2025年业绩，收益约59.44亿元，同比增长46.7%;毛利约21.39亿元，同比增长72.5%;公司拥有人应占经调整纯利约15.59亿元，同比增长69.9%;纯利同比增长38.4%至14.8亿元。集团未完成订单总量亦由2024年12月31日的9.91亿美元增长50.3%至2025年12月31日的14.89亿美元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_33.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_33.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2488822045.USD","02268","SG9999014674.SGD","BK1141"],"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621095723?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0540923850.HKD","IE00B543WZ88.USD","BK1593","LU1770034418.SGD","09926","LU0307460666.USD","LU0348767384.USD","LU2399975544.HKD","BK1583","LU2476274308.USD","CXO","LU0417516902.SGD","LU0634319403.HKD","LU0348784397.USD","LU1719994722.HKD","LU2328871848.SGD","02367","BK1585","BK1588","BK1197","BK1500","06160","IE00BPRC5H50.USD","03933","09688","LU0348766576.USD","LU0417516571.SGD","BK1191","01789","BK1207","LU0348735423.USD","06821","LU2778985437.USD","LU1115378108.SGD","LU0348827113.USD","02228","LU2488822045.USD","LU1794554557.SGD","01530","BK1141","LU0417516738.SGD","BK1574","03329","02196","BK1617","LU1303224171.USD","01099","02268","LU2476274720.SGD"],"gpt_icon":0},{"id":"2620205448","title":"港股异动 | 东曜药业-B(01875)再涨超11% 年内股价已翻倍 药明合联收购要约正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2620205448","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620205448?lang=zh_cn&edition=fundamental","pubTime":"2026-03-20 10:00","pubTimestamp":1773972047,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B再涨超11%，年内股价已实现翻倍，截至发稿，涨9.94%，报5.75港元，成交额2108.74万港元。消息面上，药明合联宣布，药明合联对东曜药业的现金要约收购已取得东曜药业60%股权之有效接纳，股份要约已正式生效。根据香港联交所披露的文件，3月17日，WuXi XDC Cayman Inc.以每股均价4.0港元场外增持东曜药业4.64亿股普通股股份，价值约18.55亿港元。增持后，其最新持股数目为4.64亿股股份，好仓比例由0.00%升至60.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"716700f540e2f30ce9084471cdfe18ec","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02268","BK1141","LU2488822045.USD","SG9999014674.SGD","01875","BK1574","BK4588","BK4585","VXUS"],"gpt_icon":0},{"id":"2620203185","title":"【券商聚焦】中国银河：“十五五”首次将生物医药列为国家新兴支柱产业，持续发力研发创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203185","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620203185?lang=zh_cn&edition=fundamental","pubTime":"2026-03-20 09:23","pubTimestamp":1773969824,"startTime":"0","endTime":"0","summary":"“十四五”规划重点关注医药创新产品产业化、医药产业化技术攻关、疫苗和短缺药品供应保障、产品质量升级、医药工业绿色低碳等五大工程，成效斐然，中国创新药获批上市数量由2015年的11款提升至2024年的92款，2024年共有22款国产化药和17款国产生物药获批上市，国产创新药占比提升至42%。“十五五”规划提出健全医疗、医保、医药协同发展和治理机制，生物医药产业首次被列为国家“新兴支柱产业”，战略定位进一步提升。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976888","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0708995583.HKD","SG9999014674.SGD","BK4585","LU1969619763.USD","02359","06881","02268","399441","LU0417516571.SGD","LU0307460666.USD","LU0348767384.USD","06990","LU1770034418.SGD","LU2778985437.USD","HK0000306685.HKD","XBI","LU0052750758.USD","HK0000320223.HKD","LU2242644610.SGD","LU2476274720.SGD","BK1147","BK1161","BK4581","BK1588","IE00B543WZ88.USD","LU2125910500.SGD","LU0348825331.USD","02696","LU0348766576.USD","BK4588","601881","BK1564","LU2328871848.SGD","LU0348735423.USD","LU2476274308.USD","09995","LU0540923850.HKD","09926","HK0000306701.USD","BK1141","06160","161726","LU2045819591.USD","LU0196878994.USD","LU0588546209.SGD","LU1720050803.USD","02162","BK0276"],"gpt_icon":0},{"id":"2620292008","title":"港股异动 | 东曜药业-B(01875)涨超9% 药明合联已取得公司60%股权有效接纳 收购要约正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292008","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292008?lang=zh_cn&edition=fundamental","pubTime":"2026-03-19 09:57","pubTimestamp":1773885457,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B涨超9%，截至发稿，涨8.02%，报4.85港元，成交额1989.09万港元。消息面上，3月18日，药明合联宣布，公司已成功获得东曜药业60%股权之有效接纳，本次收购要约已正式生效。据药明合联介绍，本次收购要约的最后可接纳截止日期为2026年3月31日下午4时，东曜药业股东将在剩余的时间里决策是否接纳本次要约。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","02268","SG9999014674.SGD","VXUS","01875","BK1161","BK1574","BK4588","BK4585","BK1141"],"gpt_icon":0},{"id":"2620449190","title":"港股异动 | 东曜药业-B(01875)午后涨超5% 药明合联收购条件到期未达成 要约期已延长","url":"https://stock-news.laohu8.com/highlight/detail?id=2620449190","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620449190?lang=zh_cn&edition=fundamental","pubTime":"2026-03-17 15:23","pubTimestamp":1773732198,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B(01875)午后涨超5%，截至发稿，涨4.04%，报43.8港元，成交额815.65万港元。消息面上，今年1月，东曜药业获药明合联溢价约99%提现金要约。据悉，本次收购成功的关键在于药明合联能否在截止日期前获得至少60%的东曜药业投票权。药明合联此前已经锁定了持有42.16%股份的五大主要股东的“不可撤销承诺”。3月13日，公司公告称，由于接纳条件于首个截止日期未获达成，要约人把首个截止日期延长至2026年3月27日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","02268","BK1161","BK4588","BK1141","BK4585","LU2488822045.USD","SG9999014674.SGD","VXUS","BK1574"],"gpt_icon":0},{"id":"1150046369","title":"港股生物医药概念股走高，药明合联涨近7%，荣昌生物涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150046369","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150046369?lang=zh_cn&edition=fundamental","pubTime":"2026-03-17 10:28","pubTimestamp":1773714505,"startTime":"0","endTime":"0","summary":"3月17日，$生物(000504)$医药概念股走高，$药明合联(02268)$涨近7%，$荣昌生物(09995)$涨超5%，$君实生物(01877)$、$诺诚健华(09969)$、$药明康德(02359)$等个股跟涨","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5f115a7e903cc298acc05fac997c6569","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK4581","BK0239","BK1161","BK4585","LU2488822045.USD","09995","BK1583","SG9999014674.SGD","BK1574","LU2148510915.USD","02268","LU1064131003.USD","LU2328871848.SGD","BK1141","BK4588","LU1064130708.USD"],"gpt_icon":0},{"id":"1154028533","title":"药明合联（02268）收购东曜药业（01875）首轮接纳达46.54%，要约延至3月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=1154028533","media":"公告速递","labels":["shareholding","merge","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154028533?lang=zh_cn&edition=fundamental","pubTime":"2026-03-13 18:36","pubTimestamp":1773398177,"startTime":"0","endTime":"0","summary":"药明合联生物技术有限公司与东曜药业股份有限公司3月13日晚联合公告，药明合联透过花旗环球金融亚洲有限公司作出的自愿有条件现金要约，于首个截止日期已收到对3.5963亿股东曜药业股份的有效接纳，占东曜药业已发行股本及表决权约46.54%。同时，购股权要约方面，共有651.26万份购股权被有效接纳，占东曜药业尚未行使购股权总额约85.33%。药明合联已将截止日期延长14日至3月27日16:00，其余条款维持不变。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"gpt_icon":0},{"id":"2618961185","title":"药明合联(02268)出现大手买入9.1万股，成交价$55.5，涉资505.05万","url":"https://stock-news.laohu8.com/highlight/detail?id=2618961185","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618961185?lang=zh_cn&edition=fundamental","pubTime":"2026-03-12 15:00","pubTimestamp":1773298800,"startTime":"0","endTime":"0","summary":"[大手成交]药明合联(02268)在下午03:00出现大手买入，成交量为9.1万，成交价为港币$55.5，涉资505.05万。至目前为止，股价跌3.733%，今日最高价为$59.4，而最低价为$55.0，总成交量为497.462万股，总成交金额港币$2.816亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603126651/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603126651/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["SG9999014674.SGD","BK1141","02268","LU2488822045.USD"],"gpt_icon":0},{"id":"2618970482","title":"【券商聚焦】中泰国际：中央政府首次将生物医药列入新兴支柱产业 预计今后将大力支持生物医药行业发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2618970482","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618970482?lang=zh_cn&edition=fundamental","pubTime":"2026-03-12 08:50","pubTimestamp":1773276634,"startTime":"0","endTime":"0","summary":"中央政府首次将生物医药列入新兴支柱产业，预计今后将大力支持生物医药行业发展。考虑到中国政府不断加强对创新药的支持力度，而且创新药出海也将增加研发外包服务的需求，因此该机构认为这些企业仍值得推荐。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976333","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","06160","BK1515","BK4581","BK1197","LU0348767384.USD","LU0634319403.HKD","LU0540923850.HKD","02228","HK0000165453.HKD","LU0348825331.USD","SG9999004311.SGD","LU1719994722.HKD","LU1251922891.USD","01099","03933","LU2476274308.USD","09688","LU2476274720.SGD","02196","LU0348827113.USD","BK1585","BK1100","LU1794554557.SGD","LU2778985437.USD","IE00B543WZ88.USD","01789","BK1617","09926","02367","LU1303224171.USD","XBI","LU1770034418.SGD","LU1720050803.USD","399441","BK4585","BK1500","IE00B5MMRT66.SGD","161726","LU0307460666.USD","LU0348784397.USD","LU0588546209.SGD","LU0348783233.USD","02268","LU0348766576.USD","SG9999014674.SGD","BK4588","BK1191","LU0640798160.USD"],"gpt_icon":0},{"id":"2618980010","title":"每日卖空追踪 | 药明合联 03月10日卖空量成交41万股，卖空比例为12.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618980010","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618980010?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 16:30","pubTimestamp":1773131429,"startTime":"0","endTime":"0","summary":"药明合联北京时间03月10日，涨2.52%，卖空量成交41万股，较上一交易日减少45.44%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163351a6b4d5d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163351a6b4d5d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1141","02268","SG9999014674.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}